Cargando…

How do mTOR inhibitors fit in the landscape of treatment for relapsed acute lymphoblastic leukemia?

Detalles Bibliográficos
Autores principales:	Pinchinat, Ashley, Raetz, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521218/ https://www.ncbi.nlm.nih.gov/pubmed/35112555 http://dx.doi.org/10.3324/haematol.2021.280395

Ejemplares similares

Targeting mTOR in Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2019)

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
por: Evangelisti, Camilla, et al.
Publicado: (2018)

Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
por: Shi, Pei-Jie, et al.
Publicado: (2016)

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia
por: Wong, Jacky, et al.
Publicado: (2014)

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells
por: Beagle, Brandon R., et al.
Publicado: (2014)

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
por: Badura, Susanne, et al.
Publicado: (2013)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia
por: Buono, Roberta, et al.
Publicado: (2023)

Biological Aspects of mTOR in Leukemia
por: Mirabilii, Simone, et al.
Publicado: (2018)

Where is mTOR and what is it doing there?
por: Betz, Charles, et al.
Publicado: (2013)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
por: Kuwatsuka, Y, et al.
Publicado: (2011)

mTOR Inhibition by Everolimus in Childhood Acute Lymphoblastic Leukemia Induces Caspase-Independent Cell Death
por: Baraz, Rana, et al.
Publicado: (2014)

Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia
por: Chang, Yoon Soo, et al.
Publicado: (2023)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model
por: Hasan, Md. Nabiul, et al.
Publicado: (2014)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?
por: Kezic, Aleksandra, et al.
Publicado: (2018)

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014)

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
por: Witzig, T E, et al.
Publicado: (2011)

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
por: Tan, Peter, et al.
Publicado: (2016)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)
por: Nemes, Karolina, et al.
Publicado: (2013)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Practical considerations for the use of mTOR inhibitors
por: Diekmann, Fritz, et al.
Publicado: (2015)

Deptor: not only a mTOR inhibitor
por: Catena, Valeria, et al.
Publicado: (2017)

Role of mTOR Inhibitors in Kidney Disease
por: Kajiwara, Moto, et al.
Publicado: (2016)

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021)

Chromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia
por: Wang, Han, et al.
Publicado: (2023)

mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
por: Jefferies, Reece, et al.
Publicado: (2022)

Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia
por: Guo, Naxin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nejo0upjj5vqvnn3b6asnlrfe4